PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Arrowhead Pharmaceuticals, Inc. (ARWR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US04280A1007

CUSIP

04280A100

Sector

Healthcare

IPO Date

Jun 16, 1993

Highlights

Market Cap

$2.33B

EPS (TTM)

-$4.65

PEG Ratio

-1.32

Total Revenue (TTM)

$3.55M

Gross Profit (TTM)

-$10.02M

EBITDA (TTM)

-$408.39M

Year Range

$17.05 - $39.83

Target Price

$47.29

Short %

8.86%

Short Ratio

9.41

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ARWR vs. PODD ARWR vs. XBI ARWR vs. QQQ
Popular comparisons:
ARWR vs. PODD ARWR vs. XBI ARWR vs. QQQ

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Arrowhead Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%20.00%JuneJulyAugustSeptemberOctoberNovember
-24.16%
12.33%
ARWR (Arrowhead Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Arrowhead Pharmaceuticals, Inc. had a return of -38.86% year-to-date (YTD) and -34.05% in the last 12 months. Over the past 10 years, Arrowhead Pharmaceuticals, Inc. had an annualized return of 12.26%, outperforming the S&P 500 benchmark which had an annualized return of 11.13%.


ARWR

YTD

-38.86%

1M

-8.69%

6M

-25.58%

1Y

-34.05%

5Y (annualized)

-17.63%

10Y (annualized)

12.26%

^GSPC (Benchmark)

YTD

24.05%

1M

1.08%

6M

11.50%

1Y

30.38%

5Y (annualized)

13.77%

10Y (annualized)

11.13%

Monthly Returns

The table below presents the monthly returns of ARWR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20244.90%-0.00%-10.90%-20.91%1.46%13.25%9.89%-16.56%-18.72%-0.72%-38.86%
2023-13.73%-7.69%-21.36%39.41%-2.82%3.63%-3.20%-19.93%-2.79%-8.49%-13.79%44.34%-24.56%
2022-20.42%-16.60%4.52%-10.61%-18.85%5.55%20.79%-6.63%-16.77%5.33%-7.50%25.96%-38.82%
20210.57%3.23%-16.76%9.73%-0.22%14.08%-16.34%-3.13%-6.99%2.23%9.76%-5.35%-13.59%
2020-33.93%-15.63%-18.64%19.67%-6.36%33.96%-0.28%-1.93%1.94%33.07%9.13%22.71%20.97%
201913.69%38.24%-5.99%-2.02%31.87%11.77%9.66%17.58%-17.53%42.12%82.30%-13.12%410.71%
201867.93%4.85%11.27%-10.96%66.98%26.87%7.13%1.30%29.88%-33.65%14.15%-14.46%237.50%
201725.16%16.49%-18.14%-16.22%-7.10%12.50%8.64%59.09%54.64%-15.94%-1.92%3.08%137.42%
2016-43.41%12.07%23.59%20.12%5.87%-13.21%12.03%16.28%6.06%-21.09%-75.17%7.64%-74.80%
2015-14.50%19.33%-10.16%2.00%-8.70%13.49%-13.57%-4.05%-2.87%-10.59%22.72%-2.69%-16.67%
201441.38%26.73%-15.53%-33.50%15.21%13.75%-11.60%15.18%1.37%-55.86%-10.74%26.80%-31.98%
2013-9.35%11.29%0.97%-5.50%6.80%-9.09%88.50%10.08%37.11%23.02%17.57%31.83%407.01%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ARWR is 20, indicating that it is in the bottom 20% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ARWR is 2020
Combined Rank
The Sharpe Ratio Rank of ARWR is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of ARWR is 1919
Sortino Ratio Rank
The Omega Ratio Rank of ARWR is 1919
Omega Ratio Rank
The Calmar Ratio Rank of ARWR is 2323
Calmar Ratio Rank
The Martin Ratio Rank of ARWR is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ARWR, currently valued at -0.55, compared to the broader market-4.00-2.000.002.004.00-0.552.46
The chart of Sortino ratio for ARWR, currently valued at -0.46, compared to the broader market-4.00-2.000.002.004.00-0.463.31
The chart of Omega ratio for ARWR, currently valued at 0.94, compared to the broader market0.501.001.502.000.941.46
The chart of Calmar ratio for ARWR, currently valued at -0.36, compared to the broader market0.002.004.006.00-0.363.55
The chart of Martin ratio for ARWR, currently valued at -1.01, compared to the broader market-10.000.0010.0020.0030.00-1.0115.76
ARWR
^GSPC

The current Arrowhead Pharmaceuticals, Inc. Sharpe ratio is -0.55. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Arrowhead Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
-0.55
2.46
ARWR (Arrowhead Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Arrowhead Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-97.44%
-1.40%
ARWR (Arrowhead Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Arrowhead Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arrowhead Pharmaceuticals, Inc. was 99.83%, occurring on Dec 16, 2016. The portfolio has not yet recovered.

The current Arrowhead Pharmaceuticals, Inc. drawdown is 97.44%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.83%Jan 25, 19963716Dec 16, 2016
-75%Dec 8, 199514Dec 29, 199512Jan 22, 199626
-66.67%Sep 28, 19956Oct 31, 19955Nov 20, 199511
-40%Nov 30, 19951Nov 30, 19951Dec 1, 19952
-30%Nov 28, 19951Nov 28, 19951Nov 29, 19952

Volatility

Volatility Chart

The current Arrowhead Pharmaceuticals, Inc. volatility is 16.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JuneJulyAugustSeptemberOctoberNovember
16.72%
4.07%
ARWR (Arrowhead Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Arrowhead Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Arrowhead Pharmaceuticals, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items